- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00134095
S-1 and Irinotecan in Treating Patients Who Are Undergoing Surgery for Locally Advanced Stomach Cancer
Phase II Clinical Study of Preoperative S-1/CPT-11 Combination Chemotherapy in Patients With Locally Advanced Gastric Cancer
RATIONALE: Drugs used in chemotherapy, such as S-1 and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving chemotherapy before surgery may shrink the tumor so that it can be completely removed.
PURPOSE: This phase II trial is studying how well giving S-1 together with irinotecan works in treating patients who are undergoing surgery for locally advanced stomach cancer.
Study Overview
Status
Conditions
Detailed Description
OBJECTIVES:
Primary
- Determine the efficacy of neoadjuvant S-1 and irinotecan in patients with locally advanced gastric cancer.
Secondary
- Determine the histological response in patients treated with this regimen.
- Determine the overall survival of patients treated with this regimen.
- Determine the progression-free survival of patients treated with this regimen.
- Determine the toxicity of this regimen in these patients.
- Determine postoperative morbidity in patients treated with this regimen.
- Determine the rate of potentially curative surgery in patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive oral S-1 on days 1-21 and irinotecan IV over 90 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo gastrectomy with lymphadenectomy. After surgery, patients resume treatment with S-1 alone as before for 1 year.
PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Fukushima, Japan, 960-1295
- Fukushima Medical University Hospital
-
Yamagata, Japan, 990-2292
- Yamagata Prefectural Central Hospital
-
-
Akita
-
Noshiro, Akita, Japan, 016-0014
- Yamamoto Kumiai General Hospital
-
-
Hokkaido
-
Asahikawa, Hokkaido, Japan, 078-8211
- Asahikawa Kosei General Hospital
-
-
Hyogo
-
Kobe, Hyogo, Japan, 650
- Kobe City General Hospital
-
-
Iwate
-
Morioka, Iwate, Japan, 020-8505
- Iwate Medical University Hospital
-
-
Yamagata
-
Tsuruoka, Yamagata, Japan, 997-8515
- Tsuruoka Municipal Shonai Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed gastric adenocarcinoma
Locally advanced disease
- Clinical stage T3-4, N0-3, M0 (according to the Japanese gastric cancer classification)
- Planning to undergo curative surgery after neoadjuvant chemotherapy
PATIENT CHARACTERISTICS:
Age
- 20 to 75
Performance status
- ECOG 0-1
Life expectancy
- Not specified
Hematopoietic
- WBC 4,000-12,000/mm^3
- Granulocyte count ≥ 2,000/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 9.0 g/dL
Hepatic
- AST and ALT ≤ 100 U/L
- Bilirubin ≤ 1.5 mg/dL
Renal
- Creatinine normal OR
- Creatinine clearance ≥ 50 mL/min
Pulmonary
- PaO_2 > 60 mm Hg on room air
Other
- Able to swallow oral medication
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior biologic therapy for gastric cancer
Chemotherapy
- No prior chemotherapy for gastric cancer
Endocrine therapy
- No prior endocrine therapy for gastric cancer
Radiotherapy
- No prior radiotherapy for gastric cancer
Surgery
- No prior surgery for gastric cancer
Other
- No other prior therapy for gastric cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
|---|
|
Progression-free survival
|
|
Overall survival
|
|
Safety
|
|
Median survival
|
|
Tumor shrinkage
|
|
Historical tumor shrinkage
|
Collaborators and Investigators
Investigators
- Study Chair: Mitsukazu Gotoh, MD, Fukushima Medical University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Stomach Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Irinotecan
- Tegafur
Other Study ID Numbers
- CDR0000439474
- FMUH-UHA-GC04-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.